SAN FRANCISCO, Jan. 02, 2024 (GLOBE NEWSWIRE) Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies
Olema Pharmaceuticals (NASDAQ:OLMA) Trading 3.4% Higher themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Olema Pharmaceuticals (NASDAQ:OLMA) and Arcutis Biotherapeutics (NASDAQ:ARQT) Critical Contrast themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Get Free Report) has earned an average recommendation of “Buy” from the six research firms that are covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12 month price objective among analysts that have covered the stock in the […]
Olema Pharmaceuticals (OLMA) Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.